ERBB2 and breast cancer: [164] Similarly, NCT05800756 is an ongoing trial in which patients with early or locally advanced HER2+ BC will receive two cycles of dalpiciclib, dual antiHER2 therapy (trastuzumab and pyrotinib) and letrozole.